메뉴 건너뛰기




Volumn 11, Issue 8, 2011, Pages 1091-1097

Emepepimut-S for non-small cell lung cancer

Author keywords

BLP 25; emepepimut S; immunotherapy; liposomal; lung cancer; MUC1; NSCLC; vaccine

Indexed keywords

BIOMIRA LIPOSOMAL PEPTIDE 25; CANCER VACCINE; CHOLESTEROL; CYCLOPHOSPHAMIDE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; EMEPEPIMUT S; LIPOSOME; MUCIN 1; PEPTIDE VACCINE; PHOSPHORYL LIPID A; PLACEBO; SERYLTHREONYLALANYLPROLYLPROLYLALANYLHISTIDYLGLYCYLVALYLTHREONYLSERYLALANYLPROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLYLGLYCYLSERYLTHREONYLALANYLPROLYLPROLINE; STIMUVAX; UNCLASSIFIED DRUG;

EID: 79959883914     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.592490     Document Type: Review
Times cited : (4)

References (41)
  • 1
    • 0035901090 scopus 로고    scopus 로고
    • Inflammation and cancer: Back to Virchow
    • Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45
    • (2001) Lancet , vol.357 , pp. 539-545
    • Balkwill, F.1    Mantovani, A.2
  • 2
    • 0014887939 scopus 로고
    • The concept of immunological surveillance
    • Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27
    • (1970) Prog. Exp. Tumor. Res. , vol.13 , pp. 1-27
    • Burnet, F.M.1
  • 3
    • 0037180757 scopus 로고    scopus 로고
    • Inflammation and cancer
    • DOI 10.1038/nature01322
    • Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7 (Pubitemid 36019639)
    • (2002) Nature , vol.420 , Issue.6917 , pp. 860-867
    • Coussens, L.M.1    Werb, Z.2
  • 4
    • 44649112492 scopus 로고    scopus 로고
    • Immunotherapy for lung cancer
    • DOI 10.1097/JTO.0b013e318174e9a7, PII 0124389420080600100014
    • Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S164-70 (Pubitemid 351786751)
    • (2008) Journal of Thoracic Oncology , vol.3 , Issue.6 SUPPL. 2
    • Bradbury, P.A.1    Shepherd, F.A.2
  • 5
    • 78049485263 scopus 로고    scopus 로고
    • Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    • Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
    • (2010) Int. J. Cancer , vol.127 , pp. 2893-2917
    • Ferlay, J.1    Shin, H.R.2    Bray, F.3
  • 8
    • 63149173595 scopus 로고    scopus 로고
    • Trends in lung cancer death rates in belgium and the Netherlands: A systematic analysis of temporal patterns
    • Van Hemelrijck MJ, Kabir Z, Connolly GN. Trends in lung cancer death rates in Belgium and The Netherlands: a systematic analysis of temporal patterns. J Community Health 2009;34:188-94
    • (2009) J. Community Health , vol.34 , pp. 188-194
    • Van Hemelrijck, M.J.1    Kabir, Z.2    Connolly, G.N.3
  • 9
    • 0346996535 scopus 로고    scopus 로고
    • Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries
    • DOI 10.1016/j.ejca.2003.08.005
    • Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur J Cancer 2004;40:96-125 (Pubitemid 37542323)
    • (2004) European Journal of Cancer , vol.40 , Issue.1 , pp. 96-125
    • Bray, F.1    Tyczynski, J.E.2    Parkin, D.M.3
  • 10
    • 57349182464 scopus 로고    scopus 로고
    • Annual report to the nation on the status of cancer 1975 - 2005 featuring trends in lung cancer tobacco use and tobacco control
    • Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975 - 2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94
    • (2008) J. Natl. Cancer Inst. , vol.100 , pp. 1672-1694
    • Jemal, A.1    Thun, M.J.2    Ries, L.A.3
  • 12
    • 77956181367 scopus 로고    scopus 로고
    • Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death
    • Navaratnam S, Kliewer EV, Butler J, et al. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010;70:110-15
    • (2010) Lung Cancer , vol.70 , pp. 110-115
    • Navaratnam, S.1    Kliewer, E.V.2    Butler, J.3
  • 14
    • 2042497140 scopus 로고    scopus 로고
    • Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung
    • DOI 10.1309/U4WG-E9EB-FJN6-CM8R
    • Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004;121:644-53 (Pubitemid 38533996)
    • (2004) American Journal of Clinical Pathology , vol.121 , Issue.5 , pp. 644-653
    • Awaya, H.1    Takeshima, Y.2    Yamasaki, M.3    Inai, K.4
  • 15
    • 0035370711 scopus 로고    scopus 로고
    • The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature
    • DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
    • Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-82 (Pubitemid 32476360)
    • (2001) Cancer , vol.91 , Issue.11 , pp. 1973-1982
    • Rahn, J.J.1    Dabbagh, L.2    Pasdar, M.3    Hugh, J.C.4
  • 16
    • 0027234998 scopus 로고
    • Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene
    • Ding L, Lalani EN, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993;36:9-17
    • (1993) Cancer Immunol. Immunother , vol.36 , pp. 9-17
    • Ding, L.1    Lalani, E.N.2    Reddish, M.3
  • 20
    • 34247854880 scopus 로고    scopus 로고
    • A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer
    • PII 0124389420060100000010
    • Nagai S, Takenaka K, Sonobe M, et al. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006;1:46-51 (Pubitemid 47164020)
    • (2006) Journal of Thoracic Oncology , vol.1 , Issue.1 , pp. 46-51
    • Nagai, S.1    Takenaka, K.2    Sonobe, M.3    Ogawa, E.4    Wada, H.5    Tanaka, F.6
  • 22
    • 70349416505 scopus 로고    scopus 로고
    • Vaccines for the treatment of non-small cell lung cancer: A renewed anticancer strategy
    • Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009;14:909-20
    • (2009) Oncologist , vol.14 , pp. 909-920
    • Gridelli, C.1    Rossi, A.2    Maione, P.3
  • 23
    • 33744546327 scopus 로고    scopus 로고
    • A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy
    • DOI 10.1016/S0022-5347(06)00494-0, PII S0022534706004940
    • North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 2006;176:91-5 (Pubitemid 43815368)
    • (2006) Journal of Urology , vol.176 , Issue.1 , pp. 91-95
    • North, S.A.1    Graham, K.2    Bodnar, D.3    Venner, P.4
  • 24
    • 33947224631 scopus 로고    scopus 로고
    • MUC1 is a novel regulator of ErbB1 receptor trafficking
    • DOI 10.1038/sj.onc.1209976, PII 1209976
    • Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007;26(12):1693-701 (Pubitemid 46426203)
    • (2007) Oncogene , vol.26 , Issue.12 , pp. 1693-1701
    • Pochampalli, M.R.1    Bejjani, R.M.E.2    Schroeder, J.A.3
  • 26
    • 34547661985 scopus 로고    scopus 로고
    • L-BLP25: A peptide vaccine strategy in non small cell lung cancer
    • 15 Pt 2
    • Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4652-4
    • (2007) Clin. Cancer Res. , vol.13
    • Sangha, R.1    Butts, C.2
  • 29
    • 79959880112 scopus 로고    scopus 로고
    • L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study
    • Suppl: abstract e13153
    • Ohyanagi F, Horai T, Sekine I, et al. L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study. J Clin Oncol 2010;28(Suppl):abstract e13153
    • (2010) J. Clin. Oncol. , vol.28
    • Ohyanagi, F.1    Horai, T.2    Sekine, I.3
  • 31
    • 0031710507 scopus 로고    scopus 로고
    • Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
    • DOI 10.1007/s002620050498
    • Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1-12 (Pubitemid 28430525)
    • (1998) Cancer Immunology Immunotherapy , vol.47 , Issue.1 , pp. 1-12
    • Bass, K.K.1    Mastrangelo, M.J.2
  • 32
    • 0029787977 scopus 로고    scopus 로고
    • Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
    • MacLean GD, Miles DW, Rubens RD, et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996;19:309-16 (Pubitemid 26313521)
    • (1996) Journal of Immunotherapy , vol.19 , Issue.4 , pp. 309-316
    • MacLean, G.D.1    Miles, D.W.2    Rubens, R.D.3    Reddish, M.A.4    Longenecker, B.M.5
  • 33
    • 65349149403 scopus 로고    scopus 로고
    • A multi-centre phase IIB randomized controlled study of BLP25liposome vaccine L-BLP25 or stimuvax for active specific immunotherapy of non-small cell lung cancer NSCLC: Updated survival analysis
    • abstract B1-01
    • Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis [abstract B1-01]. J Thorac Oncol 2007;2:S322-3
    • (2007) J. Thorac. Oncol. , vol.2
    • Butts, C.1    Maksymiuk, A.2    Goss, G.3
  • 34
    • 78649235731 scopus 로고    scopus 로고
    • A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer
    • Butts C, Murray RN, Smith CJ, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-Small-cell lung cancer. Clin Lung Cancer 2010;11:391-5
    • (2010) Clin. Lung Cancer , vol.11 , pp. 391-395
    • Butts, C.1    Murray, R.N.2    Smith, C.J.3
  • 39
    • 77953393492 scopus 로고    scopus 로고
    • Long-term safety of BLP25 liposome vaccine L-BLP25 in patients pts with stage IIIB/IV non-small cell lung cancer NSCLC
    • abstract 3055
    • Butts C, Anderson H, Maksymiuk A, et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S):abstract 3055
    • (2009) J. Clin. Oncol. , vol.27 , Issue.15 S
    • Butts, C.1    Anderson, H.2    Maksymiuk, A.3
  • 40
    • 79959900847 scopus 로고    scopus 로고
    • A multi-centre open-label study to assess the safety of stimuvax BLP25 liposome vaccine or L-BLP25 in non-small cell lung cancer NSCLC patients pts with unresectable stage III disease ASCO annual meeting proceedings part I
    • abstract 3075
    • Soulieres D, Smith C, Ellis PM, et al. A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):abstract 3075
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 S
    • Soulieres, D.1    Smith, C.2    Ellis, P.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.